Shigeatsu Endo on Muck Rack

Shigeatsu Endo

As seen in: Journal of Intensive Care
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shigeatsu

Contact Shigeatsu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

|
By Shigeatsu Endo, Ryutaro Shimazaki
| Journal of Intensive Care Verified
Antithrombin (AT), a major coagulation inhibitor in humans, is a single-chain glycoprotein with 432 amino acids and a molecular weight of approximately 58 kDa [1, 2]. AT binds and traps thrombin and other coagulation factors, including factors IX, X, XI, and XII [3, 4]. AT’s activity is enhanced 1000-fold by heparin [5]. Functional AT levels are significantly reduced in patients with congenital AT deficiency, and affected individuals are susceptible to clotting from a young age.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified